Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: Pertuzumab|DRUG: Trastuzumab|DRUG: Fulvestrant|DRUG: Capecitabine
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University